Skip to main content
TRVI logo

TRVI · Trevi Therapeutics, Inc. · Executive Compensation

Track TRVI — free
$13.49 -0.23 (-1.68%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.96B
Shares
142.56M
Volume · Nov 20 1.37M Avg daily vol (3M) 1.97M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Jennifer Good $3,944,892
James Cassella $1,637,220
Farrell Simon $1,355,897
Fiscal 2024
Executive Total
Jennifer Good $2,589,035
James Cassella $1,441,119
Lisa Delfini $1,187,403
Farrell Simon —
Fiscal 2023
Executive Total
Jennifer Good $1,687,298
Thomas Sciascia $977,125
David Clark $610,638
James Cassella —
Lisa Delfini —
Fiscal 2022
Executive Total
Jennifer Good $898,095
David Clark $580,781
Thomas Sciascia $577,295
Fiscal 2021
Executive Total
Jennifer Good $1,527,439
William Forbes $1,180,794
Thomas Sciascia $717,544
Fiscal 2020
Executive Total
Jennifer Good $1,441,457
Yann Mazabraud $716,856
Chris Seiter $716,218
Thomas Sciascia $709,894
Fiscal 2019
Executive Total
Jennifer Good $2,810,719
Yann Mazabraud $914,666
Thomas Sciascia $786,845
Fiscal 2018
Executive Total
Yann Mazabraud $1,012,833
Jennifer Good $528,250

Executive changes

Person Change Filed
David Hastings Appointed 2025-12-05
Lisa Delfini
“The Company appreciates the service of Ms. Delfini and her resignation is not the result of any disagreement with the Company on any matter, including the Company’s operations, policies or practices.”
Resigned 2025-08-20
James Cassella Resigned 2024-10-01
James Cassella Appointed 2024-10-01

Leadership

Key facts CIK 1563880 CUSIP 89532M101 13F (30d) 230 filings 216 filers Visit website Investor relations